GlassScriptPhysician profile
Steven Wayne Templeton
NPI 1831578822
$6,166.41
in general payments reported to CMS, 2019-2025
26 companies · $2,148 in 2025
The $2,148 reported for 2025 was more than what 87% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $600 · 2023: $929 · 2024: $2,490 · 2025: $2,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,832 · Travel and Lodging: $2,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.77 |
| Travel and Lodging | $2,734.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,982.86 | 2024 | |
| Noah Medical Corporation | $1,376.68 | 2025 | Galaxy |
| Glaxosmithkline, LLC. | $489.52 | 2022-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Gilead Sciences, INC. | $279.06 | 2022-2024 | Veklury |
| Insmed, INC. | $192.64 | 2022-2025 | Arikayce, Brinsupri |
| Baxter Healthcare | $184.23 | 2022-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Galvanize Therapeutics, INC | $180.21 | 2025 | Aliya System |
| Regeneron Healthcare Solutions, INC. | $178.45 | 2022-2024 | Dupixent |
| Inari Medical, INC. | $155.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $155.36 | 2022-2025 | Airsupra, Fasenra, Breztri |
| United Therapeutics Corporation | $145.21 | 2024-2025 | Tyvaso, Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.06 | 2022-2025 | Ofev, Stiolto Respimat |
| Genzyme Corporation | $101.20 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $88.34 | 2022-2023 | Opsumit, Uptravi |
| Verona Pharma, INC. | $83.46 | 2025 | Ohtuvayre |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.11 | 2023-2025 | Glassia |
| Philips North America LLC | $71.59 | 2023-2024 | (Ak6) Vest Therapy |
| Amgen INC. | $52.84 | 2022-2025 | Tezspire |
| Mylan Specialty L.P. | $52.21 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $44.98 | 2023-2024 | Winrevair |
| Ani Pharmaceuticals, INC. | $43.27 | 2024 | Purified Cortrophin Gel |
| Astellas Pharma US INC | $37.16 | 2023 | Cresemba |
| La Jolla Pharmaceutical Company | $33.03 | 2022-2024 | Xacduro |
| Viatris Specialty LLC | $20.61 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $19.54 | 2023 | Nuzyra |
| Abbvie INC. | $12.99 | 2023 | Teflaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Templeton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.